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Abstract
Blood microRNA (miRNA) levels have been associated with and shown to participate in disease pathophysiology. However,
the hematopoietic cell of origin of blood miRNAs and the individual blood cell miRNA profiles are poorly understood. We
report the miRNA content of highly purified normal hematopoietic cells from the same individuals. Although T-cells, B-cells
and granulocytes had the highest miRNA content per cell, erythrocytes contributed more cellular miRNA to the blood,
followed by granulocytes and platelets. miRNA profiling revealed different patterns and different expression levels of miRNA
specific for each lineage. miR-30c-5p was determined to be an appropriate reference normalizer for cross-cell qRT-PCR
comparisons. miRNA profiling of 5 hematopoietic cell lines revealed differential expression of miR-125a-5p. We
demonstrated endogenous levels of miR-125a-5p regulate reporter gene expression in Meg-01 and Jurkat cells by (1)
constructs containing binding sites for miR-125a-5p or (2) over-expressing or inhibiting miR-125a-5p. This quantitative
analysis of the miRNA profiles of peripheral blood cells identifies the circulating hematopoietic cellular miRNAs, supports the
use of miRNA profiles for distinguishing different hematopoietic lineages and suggests that endogenously expressed
miRNAs can be exploited to regulate transgene expression in a cell-specific manner.
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Introduction
MicroRNAs (miRNAs) function posttranscriptionally in regu-
lating gene expression by inducing mRNA degradation or
translation inhibition. More than 2000 human miRNAs have
been identified, which are estimated to regulate most (.60%)
coding genes [1,2]. miRNAs regulate genes involved in virtually all
physiologic processes and play a critical role for miRNAs in
normal lymphopoiesis [3], myelopoiesis [4], erythropoiesis [5] and
megakaryocytopoiesis [6]. Dysregulated miRNA expression and
function contribute towards the pathogenesis of numerous
hematologic diseases, including miR-29b in acute myeloid
leukemia [7], miR-145 and miR-146a in the 5q- syndrome
[8,9], mir-125b-2 in acute megakaryoblastic leukemia [10], miR-
28 in myeloproliferative neoplasms [11] and miR-155, miR-21
and miR-210 in B-cell lymphomas [12].
Besides their importance in disease pathogenesis, miRNAs are
increasingly appreciated as a sensitive class of disease biomarkers
[13,14]. miRNAs are relatively easy to measure and are
reproducible over time [15,16]. miRNAs are remarkably stable
to extremes of pH, freezing and thawing, and are much more
resistant to RNase than mRNA or ribosomal RNA [16–18]. These
characteristics most likely contribute to the ability of miRNA levels
to predict disease activity and survival [17,19]. Levels of specific
platelet miRNAs discriminate essential thrombocytosis from
reactive thrombocytosis [20] and mark platelet hyper-responsive-
ness [21]. miR-155 levels in B-cells strongly correlate with
response to therapy [22] and levels of miR-223 and miR-191
vary with the extent of platelet inhibition by thienopyridines and
aspirin [23].
Blood miRNAs circulate within cells, microvessicles, exosomes
and bound to high-density lipoproteins or Argonaute protein
[24,25]. This systemic delivery enables cell-to-cell transfer of
genetic information [26–29] and alteration of gene expression in
the recipient cell, as has been shown for T-cells to recipient
antigen-presenting cells, platelets to endothelial cells, and gut
epithelium to T-cells [30–32]. Although endothelial, epithelial and
perhaps other cells contribute to the extracellular blood miRNA
content, most circulating miRNAs are derived from hematopoietic
blood cells [33]. To better understand the role of circulating
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miRNAs in the molecular pathogenesis of hematologic diseases, it
is critical to know the cellular source of the miRNAs. Although
miRNAs have been profiled for selected hematopoietic lineages
[34–38], absolute quantification of miRNA levels across multiple
blood cell types has not been performed. The goals of our study
were to quantify the miRNA contents of normal human platelets,
T-lymphocytes, B-lymphocytes, granulocytes and erythrocytes on
a per cell and per blood volume basis, to determine whether the
expression of individual miRNAs differed by cell type, and to
explore the potential for exploiting endogenous miRNA levels to
modify exogenous gene expression in a hematopoietic cell-specific
manner. We found that nucleated cells had substantially higher
miRNA content on a per cell basis, but that the hematopoietic
cellular contribution to miRNA content of blood on a volume
basis was highest in erythrocytes, followed by granulocytes,
platelets, T-cells and B-cells. Identification of miRNAs that were
differentially expressed (DE) across hematopoietic cell lines
enabled cell-specific regulation of transgene expression.
Methods
Subjects and peripheral blood cell purification
Donors were 5 healthy males (age 32 years to 56 years), self-
identified as white race/ethnicity (Table S1). The study was
approved by the institutional review board of Thomas Jefferson
University, and written informed consent was obtained from all
subjects in accordance with the Declaration of Helsinki.
Peripheral blood cell purification
Citrated peripheral blood was collected and fractionated over
the Ficoll-Histopaque (Sigma, St. Louis, MO, USA). The platelet
rich plasma (PRP) layer was removed and platelets were pelleted
and resuspended in Beads Buffer (BB; PBS with 0.5% w/v of
bovine serum albumin and 2.5 m Methylenediaminetetraacetic
acid final concentration). Leukocytes were removed with MACS
Human CD45 microbeads reagents (Miltenyi Biotec, Auburn, CA,
USA) [39]. The mononuclear cell layer was recovered, washed
and re-suspended in BB for isolation of T-cells and B-cells using
human CD3 and human CD19 microbeads (MiltenyiBiotec,
Auburn, CA, USA), respectively. The buffy coat atop the red
blood cells was removed, washed with PBS, treated with
Erythrocyte lysis buffer (Qiagen, Hilden, Germany), pelleted and
resuspended in BB. Granulocytes were isolated using MACS
Human CD15 microbeads (MiltenyiBiotec). Lastly, erythrocytes
were isolated from the lowest Ficoll-Histopaque layer by double
immunodepletion of white blood cells and granulocytes using
Human CD45 and CD15 microbeads. Cell purity was assessed on
a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) using
FlowJo 8.5.3 software (Tree Star Inc., Ashland, OR, USA).
RNA characterization and quantification in blood cell
type and blood volume
Cell counts were determined using Hemavet 950 CBC System
(The Americas Drew Scientific Inc., CT, USA) prior to RNA
extraction. Total RNA was isolated using Trizol Reagent
(Invitrogen, Carlsbad, CA) and analyzed on an Agilent 2100
Bioanalyzer (Agilent, Santa Clara, CA), which separates nucleic
acid fragments based on their size [40]. The Agilent RNA 6000
Pico Kit was used to assess quantity and integrity of total RNA, as
well as the quantity of small (,150 bp) RNA based on area under
the curve determinations using Bioanalyzer software. The Agilent
Small RNA Pico kit was used for quantification of miRNA by
determining the fraction of small RNA that was less than 40 bp.
To estimate the contribution of each hematopoietic cell type to
miRNA content in blood volume, ‘‘cell number per blood
volume’’ was utilized from CBC count for platelets, granulocytes
and erythrocytes; CD3+ T-cell and CD19+ B-cell counts were
obtained from published reference values [41].
miRNA profiling, data normalization, relative abundance
and cluster analysis
miRNA profiling was performed using the nCounter human
miRNA assay kit v1 and v2 and analyzed with the nCounter
analysis system (NanoString Technologies, Seattle, WA, USA) [42]
and GeneSpring 12.0 GX software (Agilent Technologies, Santa
Clara, CA). A total of 623 probe sets were analyzed for all cell
types.
miRNA expression levels were normalized to the geometric
mean of the 100 highest expressed miRNAs by nSolver software
(NanoString Technologies, Seattle, WA, USA). The probe sets
from platelets, T-cells, B-cells, granulocytes and hematological cell
lines were filtered by calculating the background threshold,
defined as the mean of the negative control probe values plus 2
standard deviations (SD). Because erythrocytes showed anoma-
lously low negative control probe values, in order to not include an
excess of low expressed but biologically irrelevant miRNAs in
erythrocytes, we set the erythrocyte background expression
threshold to be similar to the other 4 cell types. For each sample,
the background was subtracted from the previous normalized
value. Raw data for primary blood cells and hematologic cell lines
has been deposited at Gene Expression Omnibus (GEO) under
accession number GSE57679.
Normalized miRNA expression levels were transformed into
relative abundance data by dividing each individual miRNA count
by the total miRNA counts in each sample. The cell type average
was calculated and ranked to determine which miRNAs were most
abundant. Exploratory cluster analysis and dendrograma were
generated using the Pearson correlation with the pairwise
complete-linkage method, and the heatmap was generated using
the HeatMap Viewer module (GenePattern software; http://www.
broadinstitute.org).
Reporter gene assays
One, two or four miRNA binding site sequences for miR-125a-
5p or a scrambled control sequence were engineered into a
luciferase 39UTR using pMIR-REPORT vector (Applied Biosys-
tem, Carlsbad, CA, USA) followed by sub-cloning into the pCDH-
MSCV-MCS-EF1-GFP vector (System Biosciences). Two million
cells per well of Meg-01, Jurkat, Raji and K562 cells were seeded
in 6-well plate and transfected with the reporter constructs.
Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) was used to
transfect Meg01 Jurkat and K562 cells; Raji cells were transfected
using Nucleofector Technology (Lonza AG, Basel, Switzerland).
Luciferase assays were performed 24 h post-transfection with the
Luciferase assay System (Promega, Madison, WI, USA) using
Fluostar OPTIMA (BMG Labtech). The GFP intensity was
quantified in a Fluostar OPTIMA (BMG Labtech). Firefly
luciferase activity was normalized to GFP intensity.
Statistical analysis
miRNAs DE among blood cells were identified by comparing
normalized miRNA levels in each cell type with the other 4 cell
types using the Welch ANOVA and post-hoc test (GeneSpring
software, Agilent, Santa Clara, CA, USA). Statistical significance
was determined by the Benjamini-Hochberg (BH) correction for
multiple testing at q-value ,0.05, with Tukey post-hoc analysis
when the miRNAs were present in all 5 cell types and the Student–
miRNA Profiling in Human Hematopoietic Cell Lineages
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Newman–Keuls post-hoc test when a miRNA was absent in one or
more cell type. Both NormFinder and Coefficient of Variation
methods were used to identify the optimal miRNA for normal-
ization across the five cell types [43]. T-tests and Spearman
correlations were performed using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA). Data are presented as mean 6
SD and p,0.05 was considered statistically significant.
Results
Contribution of peripheral blood cell types to the miRNA
content of whole blood
We determined RNA estimates for each hematopoietic cell type
in 3 stages: first, total RNA per cell type; second, miRNA per cell
type; and third, cell miRNA per blood volume. We isolated
platelets, T-cells, B-cells, granulocytes and erythrocytes from
whole blood by density centrifugation and immune-selection from
5 healthy donors. The purity of each cell preparation was greater
than 98% (Figure 1).
Total RNA per cell type. Total RNA was extracted and
quantified from 25 cell preparations (5 cell types from 5 donors).
The average total RNA yield on a per cell basis from 5 healthy
donors revealed nucleated cells contained approximately 1,000
times more total RNA than platelets or erythrocytes (fold-
difference range 323 to 3,646) (Figure 2A). On average, T-cells
contained 1.61-fold more total RNA than B cells, while B-cells
contained 2.10-fold more total RNA than granulocytes (Table 1,
row 1). Platelets contained 3.85-fold more total RNA than
erythrocytes.
miRNA per cell type. We next size-profiled the RNA
samples by electrophoretic mobility (Figure S1) and calculated
the average miRNA-to-total RNA ratio for each cell type from all
subjects. The highest miRNA:total RNA ratios were in erythro-
cytes and platelets (Figure 2B); the miRNA:total RNA ratios across
all cell types were erythrocytes.platelets.granulocytes.lympho-
cytes. These ratios, coupled with the average total RNA per cell
from Figure 2A enabled us to estimate the average miRNA mass
per cell type (Figure 2C and Table 1, row 2). T-cells and B-cells
contained similar levels of miRNAs, as did platelets and
erythrocytes; granulocytes had significant higher miRNA content
than other cell types (p values summarized in Figure 2D). On a per
cell basis, T-cells, B-cells and granulocytes contained ,100-fold
more miRNA than platelets and erythrocytes.
miRNA per blood volume. Lastly, we estimated the
contribution of each hematopoietic cell type to the miRNA
content of blood volume using cell miRNA content and cell
number per blood volume. Notably, erythrocytes contributed the
most miRNA to the blood, followed by granulocytes and platelets
(Table 1, row 3).
Figure 1. Purity of platelets, granulocytes, T-cells, B-cells and erythrocytes. Cell purity is presented as a histogram of flow cytometric data
generated with antibodies CD42, CD3, CD19, CD15 and CD235a specific for platelets, T-cells, B-cells, granulocytes, and erythrocytes, respectively. X-
axis is log fluorescence and Y-axis is cell count in6103 scale.
doi:10.1371/journal.pone.0102259.g001
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Peripheral blood miRNA profiles reveal both unique and
common expression patterns
Besides estimating the total quantities of all miRNA per blood
cell type, we quantified levels of individual miRNAs for each cell
type. Considering only the miRNAs expressed above background,
the average number of expressed miRNAs was 544 for platelets,
203 for T-cells, 256 for B-cells, 545 for granulocytes and 571 for
erythrocytes (listed in Table S2). Each cell type displayed a similar
,5 orders of magnitude dynamic range of miRNA expression
(supplemental Figure 2), and relatively few miRNAs accounted for
the majority of the total cellular content. Figure 3A illustrates the
most abundant miRNAs (63%–86% of the total miRNA content,
depending on cell type) and emphasizes differences across
hematopoietic lineages.
To consider similarities and differences among the different cell
types, we performed an unsupervised hierarchical clustering of the
most abundant miRNAs (.90% of the total miRNA content for
each cell type) (Figure 3B). The resulting dendrogram and
heatmap demonstrated that patterns of miRNA expression differ
by cell type. Notably, this unbiased analysis based on miRNA
expression matches the cell types shown at the bottom of
Figure 3B. The similarities and differences in expression patterns
were more readily apparent using the average miRNA content per
cell type (Figure 3C, left heatmap). T-cells and B-cells had similar
miRNA expression patterns that differed from granulocytes,
erythrocytes and platelets, which had unique patterns.
Transformed hematopoietic cell lines are often used as models
for primary cells, and we profiled miRNAs from Jurkat, Raji,
U937, Meg-01 and K562 cells (listed in Table S3). The patterns of
Figure 2. Quantification of total RNA and miRNA in platelets, T-Cells, B-Cells, granulocytes and erythrocytes. (A) Average yield of total
RNA from each cell type. (B) Average of miRNA fraction in the total RNA from each cell type. (C) Average miRNA content of each cell type. In (A–C) the
box represents the 25th to 75th percentiles, the line in the box is the median and the whiskers represent minimum and maximum values. (E)
Summary of comparisons across cell types in panels A–C (one tail t-test). P, platelets; T, T-cells; B, B-cells; G, granulocytes; E, erythrocytes. N = 5 for
each of the 5 cell types.
doi:10.1371/journal.pone.0102259.g002
Table 1. Contribution of hematopoietic cell type to total miRNA content per volume of blood.
Platelet T-Cell B-Cell Granulocyte Erythrocyte
Total RNA mass, femtogram/cell 2.20 2,187.97 1,360.34 646.30 0.57
miRNA mass, femtogram/cell 0.05 3.28 3.16 10.23 0.04
miRNA mass, picogram/ml blood 16.90 3.55 0.64 50.24 184.0
doi:10.1371/journal.pone.0102259.t001
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miRNA expression in transformed cell lines showed little or
modest correlation with primary hematopoietic cells (Table S4A;
in Figure 3C, right set of heatmaps, compare miR-126-3p in the
megakaryocyte/platelet lineage, miR-142-3p in the lymphocytic
lineage, etc.), whereas the cell line expression patterns showed
significant correlations among one another (Table S4B).
Peripheral blood cell source of individual miRNAs
Since different miRNAs may have different biological effects, it
is of interest to know the cellular origin of the most abundant
blood cell miRNAs. Using cell counts per volume of blood, total
miRNA mass per cell and the percentages of individual miRNAs
per cell type, we estimated the contribution of the different
peripheral blood hematopoietic cells to individual miRNAs in the
blood (Table 2). The data indicate that different peripheral blood
cells contribute unequally to the individual miRNA content in
blood. Of note, erythrocytes are the major source for many, but
not all, hematopoietic blood cell miRNAs.
Among the 623 miRNAs queried, 620 were detected in at least
one cell type, 3 miRNAs were not detected in any cell type and
165 miRNAs were detected in all the cell types (Table S5A).
Additionally, we arbitrarily defined a low expression threshold (less
than 10 miRNA counts) and a high expression threshold (greater
than 5,000 miRNA counts) (Figure S2). Using these cutoffs, 1% of
all detected miRNAs were expressed at high levels and 60% were
expressed at low levels. The numbers of miRNAs detected at low
levels were 306 for platelets, 68 for T-cells, 159 for B-cells, 295 for
granulocytes and 337 for erythrocytes. The numbers of miRNAs
detected at high levels were 23 for platelets, 19 for T-cells, 5 for B-
cells, 13 for granulocytes and 29 for erythrocyte. let-7g-5p, miR-
142-3p, miR-16-5p and miR-223-3p were expressed at high levels
in all 5 lineages, whilemiR-134, miR-517c-3p/519a-3p, miR-
518d-3p, miR-520d-5p/518a-5p/527 and miR-562 were ex-
pressed at low levels in all 5 lineages (Table S5B).
Identification of miRNAs differentially expressed (DE)
across human blood cells
miRNAs regulate gene expression and since different hemato-
poietic lineages express different repertoires of genes, it is valuable
to understand whether miRNAs are DE across human blood cells.
To compare across cell lines, miRNA expression values were
normalized, background corrected and analyzed for DE with
correction for multiple testing. We identified 93 miRNAs that
were DE among the 5 blood cell lineages (q-value,0.05 by
ANOVA). The DE miRNAs for each cell type are listed in Tables
S6A–E. Amongst miRNAs exhibiting high expression in at least
two of the hematopoietic cell lineages, we identified miR-142-5p,
miR-29a-3p, miR-150-5p and miR-93-5p as selectively reduced in
one or more primary cell types (Table S7).
Validation of DE miRNAs using qRT-PCR requires normal-
ization with an appropriate reference gene, but we were not aware
of an established appropriate normalizer for human blood cell
miRNAs. As shown in Figure 4A, analysis of our dataset identified
several potential normalizers across blood cells. We selected miR-
30c-5p as a reference normalizer gene because it was moderately
expressed and showed minimal variation across all cell types using
two different methodologies for assessing variation. The common-
ly used normalizer, RNU6B, was expressed at lower levels and
displayed more variability across the 5 blood cell types than miR-
30c-5p (Table S8). Using miR-30c-5p as a normalizer in qRT-
PCR, we validated expression levels of miR-301a-3p (Figure 4B;
r = 0.969, p-value = 0.003). Four additional miRNAs were used to
validate consistent differential expression of miRNAs across the 5
cell types using two different RNA preparations (Figure 4C–D).
Development of a model for exploiting endogenous
miRNAs to modify exogenous gene expression
To test the hypothesis that endogenous miRNA levels could be
exploited to modify transgene expression, we selected miR-125a-
5p, which was expressed at very low levels in the lymphocytic cell
lines, Jurkat and Raji, and high levels in Meg-01 and K562 cells
(Figure 5A). We generated a construct containing a luciferase
reporter with a 39UTR containing 1, 2 or 4 tandem miR-125a-5p
binding sites or scrambled control (Figure 5B). Greater repression
of reporter gene expression was observed with the four binding site
construct than with the one or two binding site constructs
(Figure 5C). Hematological cell lines transfected with only Luc-
4x125a or Luc-4xSCR demonstrated lack of transgene repression
in Raji and Jurkat cells and ,60% repression in Meg01 and K562
cells (Figure 5D), consistent with the endogenous expression shown
in Figure 5A. To assess whether miR-125a-5p directly alters
reporter gene repression, we co-transfected Luc-4x125a with an
inhibitor of miR-125a-5p and observed enhanced expression in
Meg-01 cells, whereas over-expression of miR-125a-5p repressed
reporter gene expression in Jurkat cells (Figure 5E).
Discussion
Circulating blood miRNAs systemically regulate gene expres-
sion and are emerging as important disease biomarkers. We report
an unbiased, genome-wide profiling and cross-lineage comparisons
of 623 miRNAs from highly purified normal primary human
blood platelets, T-cells, B-cells, granulocytes and erythrocytes. The
major findings were (1) miRNA profiles differ by hematopoietic
lineage, (2) the miRNA content of nucleated cells is approximately
100-fold higher than non-nucleated cells, but erythrocytes
contribute the most miRNA mass on a per volume basis (rank
order is erythrocyte.granulocyte.platelet.T-cell.B-cell), and
(3) differential cell miRNA content can be exploited to regulate
exogenous gene expression. We also provide more precise
estimates of blood cell RNAs than have been previously reported,
and identify appropriate miRNAs for normalization when
comparing miRNA measures across hematopoietic cell types.
These findings provide a potential refinement for hematopoietic
lineage classification, a framework for designing and interpreting
miRNA-disease association studies and opportunities to design
gene expression vectors that minimize off-target effects.
Estimates of blood cell total RNA content is of interest for
optimal design and interpretation of gene expression and
biomarker studies. In addition, assessing lineage-specific gene
expression requires isolating RNA from highly purified cells. Most
Figure 3. Peripheral blood cells miRNA profiles. (A) Pie graph representation of the top 10 most abundant miRNAs in each cell type. (B)
Unsupervised hierarchical clustering of miRNA expression profiles. The dendrogram was generated using the union of the 20 most abundant miRNAs
(39 in total) in each cell type. Data from 24 samples was used in these analyses (one granulocyte sample was not analyzed due to technical issues). (C)
The left heatmap is derived from the average of the miRNAs shown in panel B. For ease of comparison, the right set of heatmaps display primary
miRNA profiles adjacent to corresponding profiles from transformed cell lines, Jurkat (T-lymphoblastic), Raji (B-lymphoblastic), U937 (monocytic),
Meg-01 (megakaryoblastic) and K562 (erythroleukemic) cell lines. Each column in the heatmaps indicates the average log-ratio intensity data. *
indicates probes with similar and indistinguishable sequence with the nCounter platform.
doi:10.1371/journal.pone.0102259.g003
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prior estimates of blood cell total RNA or miRNA content used
density centrifugation for cell purification [38,44,45] or could not
make quantitative estimates [46]. Unfortunately, density centrifu-
gation alone results in substantial leukocyte contamination of
platelet and erythrocyte preparations [47], compromising esti-
mates of the RNA content of non-nucleated cells because of the
higher RNA content of nucleated cells. We used density
centrifugation followed by immunoselection with cell-specific
markers to isolate highly purified populations, an approach
considered state-of-the-art for RNA expression analyses
[37,48,49]. The purification procedure used in the current report
yields less than 1 leukocyte per 5 million platelets [21]. In addition,
by using the numbers of cells from which RNA was extracted, we
were able to make quantitative estimates of RNA per cell. We
found the total RNA mass per leukocyte (0.646–2.188 picogram)
and per erythrocyte (0.60 femtogram) were similar to other reports
[37,45]. We estimated a total RNA content of 2.20 femtograms
per platelet. Prior estimates of platelet RNA content were based on
Table 2. miRNA repertoire per blood volume unit.
Gene Name Platelets T-cells B-cells Granulocytes Erythrocytes
let-7a-5p 5% 1% 0% 3% 91%
let-7b-5p 1% 0% 0% 1% 98%
let-7d-5p 36% 2% 1% 24% 38%
let-7f-5p 27% 3% 0% 14% 56%
let-7g-5p 7% 4% 1% 8% 80%
let-7i-5p 15% 1% 0% 4% 80%
miR-103a-3p 48% 2% 0% 47% 2%
miR-106a-5p/17-5p* 0% 0% 0% 0% 99%
miR-106b-5p 2% 0% 0% 9% 89%
miR-1260a 4% 17% 8% 63% 8%
miR-126-3p 43% 0% 0% 0% 56%
miR-142-3p 13% 5% 1% 58% 23%
miR-142-5p 4% 8% 1% 87% 0%
miR-144-3p 8% 0% 0% 2% 90%
miR-148a-3p 8% 1% 0% 57% 35%
miR-150-5p 0% 84% 10% 5% 1%
miR-15a-5p 4% 0% 0% 13% 83%
miR-15b-5p 4% 0% 0% 7% 89%
miR-16-5p 4% 1% 0% 13% 82%
miR-191-5p 19% 1% 0% 36% 44%
miR-199a/b-3p* 89% 0% 0% 10% 1%
miR-19b-3p 11% 2% 0% 13% 73%
miR-20a/b-5p 8% 1% 0% 9% 81%
miR-21-5p 21% 8% 1% 15% 55%
miR-223-3p 7% 0% 0% 92% 2%
miR-23a-3p 35% 1% 0% 63% 1%
miR-24-3p 46% 2% 0% 47% 5%
miR-25-3p 4% 1% 0% 13% 82%
miR-26a-5p 27% 6% 1% 56% 10%
miR-26b-5p 0% 0% 0% 1% 98%
miR-29a-3p 8% 10% 2% 80% 0%
miR-29c-3p 9% 11% 2% 57% 21%
miR-30b-5p 10% 4% 1% 14% 71%
miR-342-3p 3% 58% 6% 16% 17%
miR-374a-5p 2% 0% 0% 2% 96%
miR-451a 0% 0% 0% 0% 99%
miR-720 12% 9% 2% 75% 1%
miR-92a-3p 18% 3% 1% 11% 67%
miR-93-5p 1% 0% 0% 1% 98%
Note: each row totals 100%
* Probes with similar and indistinguishable sequence in this assay.
doi:10.1371/journal.pone.0102259.t002
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an uncertain number of platelets derived from density centrifuga-
tion of buffy coats [44]. Taken together, we conclude that platelets
have a slightly higher total RNA content than erythrocytes, but
that leukocytes have approximately 1,000 times more RNA than
platelets or erythrocytes.
We also estimated absolute miRNA quantities per hematopoi-
etic cell and per blood volume. As expected, T-cells, B-cells and
granulocytes had higher miRNA contents than platelets and
erythrocytes, most likely because of the greater size and ongoing
transcription in leukocytes. However, compared to nucleated cells,
platelets and erythrocytes had a higher fraction of miRNA
(Figure 2B). Because platelets and erythrocytes have no new
RNA synthesis, this difference may simply reflect greater stability
of miRNA compared to larger RNAs [18]. There is no reason to
expect that platelets and erythrocytes endocytose miRNA to a
greater extent than do T-cells, B-cells and granulocytes. One could
speculate that circulating non-nucleated cells have evolved to
require alternate means of regulating protein translation to
maintain viability during their 10 day (platelets) or 120 day
(erythrocytes) lifespans. Lymphocytes contain abundant miRNAs
and the low miRNA:total RNA ratio (Figure 2B) is likely due to the
high content of total RNA.
Although granulocytes, T-cells and B-cells had a much greater
abundance of miRNA than platelets or erythrocytes on a per cell
basis, erythrocytes, granulocytes and platelets contribute the most
miRNA to the content of blood (contribution to blood volume
erythrocyte.granulocyte.platelet.T-cell.B-cell). The greater
contribution of erythrocytes and platelets to blood volume reflects
the considerably higher numbers of these cells in blood compared
to leukocytes. Considering the relative abundance of microvessi-
cles originating from these cells [50], erythrocytes, granulocytes
Figure 4. miRNAs DE by cell type. (A) The 10 most stable miRNAs across all cell types are shown for both NormFinder (left) and Coefficient of
Variation (CV) methods (right). (B) Validation of NanoString-derived data for miR-301a-3pby qRT-PCR data. The X-axis represents the expression level
of each miRNA normalized to miR-30c-3p using 22DCt method. Each point represents the mean6 SEM of 5 subjects for each cell type. (C,D) Validation
of microRNAs DE by cell type. The NanoString-derived data for the indicated miRNAs was validated by qRT-PCR using RNA isolated from the 5
hematopoietic cell types from two different preparations of cells and RNA. qRT-PCR data was normalized and presented as in Figure 4B.P, platelets; T,
T-cells; B, B-cells; G, granulocytes; E, erythrocytes.
doi:10.1371/journal.pone.0102259.g004
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and platelets have the potential to have the greatest effect on the
systemic effect of miRNA delivery.
Numerous miRNAs were identified as DE across cell types.
Although we used qRT-PCR to validate selected miRNA
expression levels, we cannot exclude platform-specific miRNA
differences that might affect our results. However, such biases
would not be expected to be cell-specific, and should not affect our
findings of miRNAs DE by cell type. The only hematopoietic cell
miRNA profiling study of a large sample size is the Platelet RNA
And eXpression-1 (PRAX1) [49]. PRAX1 profiled highly purified
platelets and included a heterogeneous population of 154 healthy
subjects. Our platelet miRNA profiles showed a very high
correlation (p = 5.92610-19) with PRAX1 (Figure S3). Larger
studies are needed to address miRNA cell-type dependency and
the effects of disease or other demographic variables. Such
genome-wide screens require validation, and we determined miR-
30c-5p to be an ideal internal normalizer for qRT-PCR
validation. Notably, miR-30c-5p was superior to the commonly
used normalizer RNU6B, and we would discourage the use of the
latter for normalization purposes. Individual miRNAs that were
DE by cell type may be useful for identifying the cell of origin of
biomarkers or microvessicles and for offering a framework for
understanding pathophysiology. In addition, patterns of miRNA
expression were highly correlated with cell lineage defined by
surface antigens (Figure 3B), consistent with work using mRNA
profiles from the Orkin laboratory [51]. Future studies are needed
to evaluate miRNA profiles as markers of hematologic disease
activity and response to treatment, and to assess whether these DE
miRNAs are involved in lineage differentiation.
Several cell-preferentially expressed miRNAs are worth noting.
Nearly half the total erythrocyte miRNA content was represented
by miR-451a (Figure 3A), a finding consistent with its established
critical function in erythroid differentiation [52–54] and in
erythrocyte susceptibility to oxidative stress viamiR-451a-induced
repression of 14-3-3j [52,54]. Similarly, we observed high levels of
miR-150 in both T-cell and B-cells, consistent with the role of this
miRNA in lymphoid cell differentiation via its regulation of the c-
Myb transcription factor [55]. Older literature refers to miR-223
as myeloid-specific, but the high level we observed in platelets is
consistent with other reports [56,57], and high levels were also
found in Meg-01 cells that display megakaryocytic properties. We
found miR-223 to be the most abundant granulocyte miRNA,
consistent with another report using peripheral blood [58] and
with the increased expression of miR-223 that occurs during
granulocyte differentiation [59,60]. It is well-accepted that miR-
223 regulates granulocyte differentiation and function, although
the exact molecular mechanism appears complex since ectopic
expression of miR-223 in leukemic cells enhanced myeloid
differentiation [59], whereas deletion of miR-223 in a murine
model supported a negative regulatory effect on granulocyte
differentiation [60].
Even when tissue-preferential promoters are used to direct
transgene expression, off-target and deleterious effects have been
observed [61,62]. The tissue-preferential expression of miRNAs
has been exploited to prevent off-target effects in gene therapy
studies of mouse models of hemophilia [63]. Brown et al.
demonstrated that mir-142-3p effectively suppressed transgene
expression in hematopoietic lineages in mice, whereas expression
was maintained in non-hematopoietic cells [64]. This data is
consistent with the identification of mir-142-3p as one of 5 highly
expressed miRNAs among human peripheral blood cells in our
current study. Such a gene therapy approach for hematologic
diseases requires knowledge of miRNA levels in different
hematopoietic lineages. In the current study, we provide potential
miRNAs that could be used to restrict transgene expression to a
particular blood cell type (Tables S6 and S7), and demonstrated
reporter gene expression could be regulated by endogenous levels
of miR-125a-5p; high levels of miR-125a-5p suppressed expres-
sion in a megakaryocytic cell line (Meg-01), whereas low levels of
miR-125a-5p permitted expression in the lymphocytic-like cell
lines (Raji and Jurkat). Unfortunately, the levels of miRNAs
identified in primary cells did not correlate well with those
detected in the different hematopoietic cell lines (Table S4). Thus,
we cannot extrapolate that miR-125a-5p would be a useful target
for restricting transgene expression in primary cells. But for the
purpose of testing the hypothesis of exploiting endogenous levels,
our data using this miRNA established the potential for developing
gene therapy vectors that exploit hematopoietic lineage-preferential
miRNA expression.
In summary, we have quantified the total RNA and miRNA
contents of normal blood hematopoietic cells and identified
miRNAs that are DE in a cell-preferential manner. These data
can be utilized as a basis for interpretation of miRNA-disease
association studies. For example, if a particular miRNA is
elevated in acute myelogenous leukemia (AML), but absent or
very low in normal granulocytes (our data), this would suggest
this miRNA may participate in the pathogenesis of AML.
Knowledge of miRNAs DE by blood cell type is also relevant for
understanding the systemic effects of blood cell delivered
miRNAs. Since all hematopoietic blood cells release microves-
sicles upon activation, knowledge of these DE miRNAs is
expected to be helpful in understanding systemic effects in
response to inflammatory and thrombotic stimuli. Lastly, the
demonstration that endogenous miRNA levels can be utilized to
regulate transgene expression in hematopoietic cell lines suggests
an in vitro approach for improving the assessment of gene effects
in heterogeneous populations of cultured cells. Considerably
more work would be needed to evaluate the value of altering
expression vector design for gene therapy of hematological
diseases.
Supporting Information
Figure S1 Characterization of the small RNA quantities
in the total RNA. (A–E) Representative total RNA integrity
profiles for each of 5 cell lines using a total eukaryote RNA chip in
the Agilent 2100 Bioanalyzer. (F) Mean in percentages of small
RNA in the total RNA. The fraction of small RNA in the total
RNA was calculated from the area under the curve method using
image J software (Agilent 2100 Bioanalyzer). The box represents
Figure 5. Exploiting endogenous miRNAs to modify exogenous gene expression. (A) Illustration that miR-125a-5p was selectively reduced
in the lymphocytic cell lines, Jurkat and Raji. (B) Schematic of reporter constructs used to assess effect of endogenous levels of miR-125a-5p.
Constructs were engineered to contain 1, 2 or 4miR-125a-5p binding sites or scrambled sequence controls. (C) Meg-01 cells were transfected with the
indicated constructs. Luciferase repression was enhanced with more miR-125a-5p binding sites. (D) Meg-01, Raji, Jurkat and K562 cells were
transfected with the 4xSC and 4x125 constructs. Luciferase was quantified and normalized to GFP for transfection efficiency. Data plotted as fold-
expression compared to constructs with scrambled sequence. (E) Meg-01 cells were co-transfected with Luc-4x125 construct and control locked
nucleic acid (LNA) or LNA that specifically inhibits miR-125a-5p. Jurkat cells were co-transfected with Luc-4x125 construct and control pre-miRNA or
pre-miR-125a-5p. Data in panels C-E are mean 6 SD of at least three independent experiments with two replicates each.
doi:10.1371/journal.pone.0102259.g005
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the 25th to 75th percentiles, the line in the box is the median and
the whiskers represent minimum and maximum values. Data from
5 subjects (n = 25 samples) was used in these analyses.
(TIF)
Figure S2 Human peripheral blood cell miRNA expres-
sion distribution. All miRNAs expressed above background are
represented on this plot. The individual miRNAs are arbitrarily
ordered on x-axis from lowest to highest expressed, and for clarity
are represented as a line for each cell type (a bar graph would be
visually difficult to present in a single plot). Y-axis is miRNA
expression levels in log10 scale and demonstrates a similar ,5
orders of magnitude dynamic range of miRNA expression for all
cell types. Horizontal dashed lines indicate arbitrary high and low
expression thresholds.
(TIF)
Figure S3 Platelet miRNA expression correlations. The
50 highest expressed platelet miRNAs were considered from the
current study and the PRAX1 study (Edelstein et al. Nat Med
2013). (A) Venn-diagram showing 47 of 50 miRNAs were shared
between both studies. (B) Pearson correlation between miRNAs in
both studies. Points represent the mean of 5 subjects in the current
study and the mean of 154 subjects in the PRAX1 study.
(TIF)
Table S1 Demographic table.
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Table S2 miRNA profile in peripheral blood cells.
(XLS)
Table S3 miRNA profile in hematopoietic cell lines.
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Table S4 A: Correlations between hematopoietic cell line and
primary cell miRNA profiles. B: Correlations between hemato-
poietic cell line miRNA profiles.
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Table S5 A: Number of miRNA non-detected and detected. B:
Number of miRNAs with low or high expression levels.
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Table S6 A: miRNAs DE in platelets compared with all other
cell types. B: miRNAs DE in T-cells compared with all other cell
types. C: miRNAs DE in B-cells compared with all other cell types.
D: miRNAs DE in granulocytes compared with all other cell types.
E: miRNAs DE in erythrocytes compared with all other cell types.
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Table S7 Selectively reduced miRNAs amongst abun-
dantly expressed miRNAs.
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Table S8 miR-30c-5p validation.
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